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Abstract in German (Zusammenfassung) 
 
Ziel: Ziel dieser Studie war die Beurteilung der Mitralklappenanatomie, -geometrie und 
-beweglichkeit von gesunden Probanden (Kontrollgruppe) und von Patienten mit funktioneller 
Mitralklappeninsuffizienz (FMR) durch MSCT über den gesamten Herzzyklus mit Fokus auf der 
Planung  von Transkatheter-Mitralklappe Verfahren bei deren Planung das MSCT einen hohen 
Stellenwert hat. 
Material und Methoden: Datensätze von 24 Patienten ohne Mitralklappenerkrankung und 22 
Patienten mit FMR, bei denen eine EKG-getriggerte MSCT durchgeführt wurde, wurden 
retrospektiv ausgewertet. Das Durchschnittsalter betrug 47 ± 11 gegenüber 63 ± 7 Jahren (p 
<0,05), männliches Geschlecht 75% gegenüber 68% (ns), BMI 26 ± 2,8 kg / m² gegenüber 26 ± 
3,5 kg / m² (ns), LVEF 72 ± 6% vs. 31 ± 9% (p <0,05), LVEDD 55,3 ± 5,4 vs. 81 ± 11 mm (p 
<0,05). Die Ausmessung der Oberfläche des Mitralanulus (MA), des gesamten Umfangs, des 
projizierten Umfangs des Annulus, der Trigon-Trigon-Distanz und der Septum-zu-Lateralwand-
Abstände für den sattelförmigen und D-förmigen Mitralanulus und die Anulushöhe für den 
sattelförmigen Anulus, den Aorto-Mitralen- Winkel, der Linker Vorhof (LA)-zu- Linker 
Ventrikel (LV)-Achsenwinkel und der Abstand zwischen MA und Papillarmuskeln wurde für 
alle Patienten in beiden Gruppen für zehn 10% Phasen Intervallen während des gesamten 
Herzzyklus durchgeführt.  
Ergebnisse: Die mittlere 3D MA-Fläche betrug 12 ± 2 cm² in der Kontrollgruppe und 14,6 ± 
0,52 cm² bei Patienten mit FMR, die D-förmige Anulusfläche war 10,3 ± 1,6 cm² und 12,7 ± 0,5 
cm². Diese Werte waren zwischen den zwei Gruppen und beiden Methoden signifikant 
unterschiedlich. Der Trigon-zu-Trigon-Abstand war bei Patienten mit FMR signifikant größer 
als bei gesunden Probanden; 33,7 ± 1,9 mm vs. 34,6 ± 4 mm (P <0,05). Der mittlere Aorten–
Mitralwinkel lag bei gesunden Probanden bei 55 ± 7° gegenüber 46 ± 6,8° bei Patienten mit 
FMR. Darüber hinaus ist die Beweglichkeit des Mitralanulus bei gesunden Probanden höher als 
bei Patienten mit FMR. 
Schlussfolgerung: Es gibt signifikante Unterschiede in der Mitralanulus-Morphologie zwischen 
gesunden Probanden und Patienten mit FMR sowie der Morphologie bzw. Beweglichkeit des 
Mitralanulus während des gesamten Herzzyklus.  Anbetracht der geringen Beweglichkeit des 
Mitralanulus bei Patienten mit FMR und seiner größten Größe in der diastolischen Phase könnte 
die mehrphasige MSCT bei der Planung einer TMVI beispielsweise durch zweiphasige Scans 
ersetzt werden. Dies spielt eine wichtige Rolle bei der präprozeduralen Analyse und bei der 
Reduzierung der Strahlendosis, jedoch ist die Verwendung von Mehrphasen-CTA in 
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komplizierten Fällen sicher immer von Vorteil. Zusammenfassend zeigt unsere Studie, dass eine 
nicht-invasive und umfassende Beurteilung der Mitralklappe mittels MSCT möglich ist. 
 




Abstract in English (Summary) 
Objective: The objective of this study was to assess the mitral valve anatomy, geometry and 
mobility of control group and of patients with functional mitral regurgitation (FMR) by MSCT 
throughout the entire cardiac cycle in regards of optimizing the planning of transcatheter mitral 
valve procedures. 
Materials and methods: 24 healthy patients vs. 22 patients with varying degrees of FMR who 
had undergone ECG gated CTA were evaluated retrospectively. The mean age was 47 ± 11 vs. 
63 ± 7 years (p<0.05), male gender 75% vs. 68% (ns), BMI 26 ± 2.8 kg/m² versus 26 ± 
3.5 kg/m² (ns), LVEF 72 ± 6% vs. 31 ± 9% (p<0.05), LVEDD 55.3 ± 5.4 vs. 81 ± 11 mm 
(p<0.05). The evaluation of MA surface, entire circumference, projected circumference, trigone-
to-trigone distance, and septal-to lateral distances for saddle-shaped and D-shaped mitral 
annulus, and annulus height for saddle-shaped annulus, aorto-mitral annular angle, LA to LV 
axis angle and MA to papillary muscles distance was carried out for all patients in both groups 
for ten 10% intervals throughout the cardiac cycle.  
Results: The mean MA saddle-shaped annular area averaged 12 ± 2 cm² in the control group, 
14.6 ± 0.52 cm² in patients with FMR, the D-shaped annular area averaged 10.3 ± 1.6 cm² vs. 
12.7 ± 0.5 cm², respectively, thus representing a significant difference between the two groups 
and both models. The trigone-to-trigone distance was slightly larger in patients with FMR than 
in healthy subjects, namely 33.7 ± 1.9 mm vs. 34.6 ± 0.4 mm (p<0.05). The aorto-mitral angle 
mean for healthy subjects was 55 ± 7° vs. 46 ± 6.8° in patients with FMR. The mobility of the 
mitral annulus was higher in healthy patients than in patients with FMR.   
Conclusion: This study showed that there are significant differences in the mitral annular 
morphology between controls and patients with FMR, as well as several changes between 
different sizing approaches of the mitral annulus throughout the entire cardiac cycle. 
Considering the low mobility of the mitral annulus in patients with FMR and its biggest size in 
diastolic phase, multiphase MSCT might  be replaced by dual-phase scans for example  when 
planning TMVI.  This plays an important role in timing the pre-procedural analysis and in 
reducing radiation dose. However, using multiphase CTA should still be the favored mode in 
complicated cases.  In summary, our study demonstrates that a non-invasive and comprehensive 





Key Words: mitral valve, mitral annulus, mobility, functional mitral regurgitation, computed 
tomography, transcatheter mitral valve replacement. 
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1 INTRODUCTION  
 
1.1 Background 
Mitral valve disease is one of the most prevalent valvular heart diseases causing significant 
mortality and morbidity. The mitral valve is the left-sided bicuspid atrioventricular valve. It 
consists of anterior and posterior leaflets and separates the left atrium from the left ventricle. 
Embryologically, it forms from the endocardial cushions between the 5th and 8th week of 
development (1). Symmetrical apposition (a minimal overlap of about 4-5 mm) and complete 
coaptation of both leaflets is essential in preventing regurgitation (2). Mitral regurgitation (MR) 
affects almost every 1 in 10 individuals over 75 years of age (3-5). 
 
1.2 Mitral valve anatomy   
The MV apparatus is a dynamic and complex anatomical structure (6). It consists of the three-
dimensional, non-circular, saddle-shaped, highly dynamic mitral annulus, anterior and posterior 
mitral valve leaflets, a highly individualized subvalvular apparatus (fibrous tendinous chords and 
the papillary muscles), the left ventricle (LV) and the left atrium (LA). Any abnormality in any 
of these components may cause mitral dysfunction (7). The MV is very closed to the left 
ventricular outflow tract (LVOT), the left circumflex artery and the coronary sinus (8). Thus, a 
detailed pre-procedural analysis is imperative for patient selection and preoperative procedural 
planning. 
1.2.1 Mitral annulus and leaflets 
The mitral annulus is a complex and nonplanar geometric structure with a greater commissural 
diameter (long axis) and a smaller septolateral diameter (short axis) (1). The normal mitral 
annulus is non-planar and saddle-shaped fibrous ring (9). Both leaflets are attached to the 
annulus ring. The anterior leaflet is anchored to the fibrous part of the annulus. The anterior part 
of the annulus by its fibrous nature  is more rigid than the posterior part and is very closely 
associated with the aortic annulus (10). The posterior part is muscular and thus prone to 
pathological ventricular remodeling (2). The anterior mitral leaflet has a triangular shape and is 
usually larger and thicker than the posterior one. The aortic fibrous continuity of the anterior 
mitral leaflet is known as the aortic mitral curtain. The posterior leaflet has a longer attachment 
to the annulus (2). Using the Carpentier nomenclature, the indentations of the free edge of the 
posterior leaflet are defining three scallops; P1 is the most lateral scallop, P2 the middle scallop, 
and P3 the most medial scallop (11).  The anterior leaflet has no indentation and is divided into 
the three zones located opposite the posterior scallops (known as A1, A2 and A3, respectively) 
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(12-14). The points where leaflets are attached to each other are known as posteromedial and 
anterolateral commissures. Fibrous thickening external to the mitral valve commissures are 
called trigones.  
1.2.2 Subvalvular apparatus 
The mitral leaflets are connected to papillary muscles by the chordae tendineae (14). The 
anatomy of the subvalvular apparatus is highly variable because of multiple anatomic variations 
in the posterior papillary muscle (PM) and the number of chordae tendineae. The anterior PM 
has a single insertion, whereas the posterior PM exhibits multiple heads and insertions (7). There 
are three main groups of morphological variants of the papillary muscle anatomy (15). In the 
first group, PM has one head and one insertion part (10, 15). PMs with apical part divided into 
two heads along a sagittal plane belong to the second group. The ventral head is related to the 
anterior leaflet of the mitral valve and the dorsal head gives rise to the chordae tendineae 
supporting the posterior leaflet. The conjoined parts of the two heads are connected to the 
commissural zone (10). PMs with three or more heads make up the third group (7). The head 
related to the commissural zone is found between the ventral and dorsal heads. The dorsal head 
supports the posterior leaflet and the ventral head supports the anterior leaflet of the mitral valve 
(10). The second and third groups also have several subtypes, demonstrating just how variable 
the anatomy of the PM is (7, 15, 16). The superolateral papillary muscle is supplied by one or 
more branches of the circumflex artery, or by diagonal branches, whereas the inferoseptal 
papillary muscle is supplied by a single branch of the circumflex or right coronary artery, 
depending on the coronary artery dominance. Because of its single vascular supply, the 
inferoseptal muscle is susceptible to coronary ischemia (5, 17). 
The fibrocollagenous tendinous cords, or chordae tendineae, originate from the papillary 
muscles, bifurcate several times, and attach to the free edges and ventricular aspects of both 
leaflets, thus preventing marginal prolapse and aligning the zone of coaptation (18). The 
posteromedial PM chords attach to the medial half of both MV leaflets (i.e. posteromedial 
commissure, P3, A3 and half of P2 and A2). Similarly, the anterolateral PM gives chords to the 
lateral half of the leaflets (i.e. anterolateral commissure, A1, P1 and half of P2 and A2) (2). The 
chords are thinnest at their sites of insertion in the leaflets, and this is the site of predilection for 
chordal rupture. There are three types of chordae tendineae depending on their attachment (2, 
18). Primary chords attach to the free edge of the rough zone of the leaflets. They maintain the 
leaflet apposition and valve closure and their dysfunction leads to an acute MR (19). Secondary 
chords attach to the ventricular surface of the leaflet in the region of the rough zone (18). The 
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largest and thickest two of the secondary chords of the anterior mitral leaflet called strut chords 
and arise from the tip of each papillary muscle and are thought to be the strongest (2, 18). They 
are responsible for the fibrous continuity of the mitral annulus with the left ventricular 
myocardium. Strut chords are under constant tension and maintaining the shape and size of the 
left ventricle. Their transection results in alterations in the left ventricular geometry and can lead 
to left ventricular remodeling (17). The tertiary chords (the basal chords) are found in the mural 
(posterior) leaflet only which has a basal zone, and attach directly to the ventricular wall (17, 
20). 
 
1.3   Mitral regurgitation 
A reduction or elimination of the normal systolic coaptation between anterior and posterior 
mitral leaflets are the cause of mitral regurgitation in all cases, and a particular cause might 
produce regurgitation by different mechanisms (21). MR can generally be classified as ischemic 
and non-ischemic based on the underlying pathology, or based on the mechanism, which is 
generally divided into two types: primary (organic) MR and secondary (functional) MR.  
The classification proposed by Carpentier in 1972 described three classic mechanisms of MR 
(11). According to classification, MR without pathologic leaflet motion should be described as 
Type I dysfunction. It occurs due to pathologies such as annular dilatation or leaflet perforation 
(11, 20, 22). MR due to excessive leaflet motion from degenerative changes of the leaflets or 
chordae tendineae should be described as Type II dysfunction (11, 23). Type III dysfunction  
occurs due to restricted leaflet motion (leaflet tethering) caused by rheumatic disease or 
displacement of  papillary muscles secondary to left ventricular dilatation (23, 24). 
Non-ischemic primary mitral regurgitation is called degenerative mitral regurgitation (DMR) 
(Carpentier type II dysfunction) and is caused by a primary abnormality of components of the 
mitral valve apparatus, such as chordae tendineae rupture (fibroelastic deficiency, traumatic, or 
due to endocarditis), congenital leaflet cleft, inflammatory changes,  myxomatous leaflet disease, 
iatrogenic injury due to radiation or drugs, or calcification of the mitral annulus (24). 
Myxomatous degeneration is seen more frequently in younger patients, is usually associated 
with mitral annulus dilatation and characterized by a redundancy of tissue that appears to be 
myxomatous in histopathological analysis (25). Fibroelastic degeneration is generally seen in 
elderly patients and is characterized by a single lesion without tissue redundancy. In such 
patients, the mitral annulus is found to be normal or slightly dilated (26). 
Secondary or functional MR (FMR) is seen in mitral leaflets that are structurally intact but show 
tethering and retraction of the leaflet bodies (27) due to changes in the ventricular geometry 
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resulting in failure of leaflet coaptation due to other cardiac diseases, such as ischemic or dilated 
cardiomyopathy, myocarditis or any other cause of LV dysfunction. Recent investigations, 
however, show significant MV leaflet tissue changes (extracellular matrix changes) and an 
increased leaflet thickness and length as signs of structural leaflet remodeling (28, 29). Several 
underlying mechanisms may contribute to FMR. These include LV remodeling, wall motion 
abnormalities, displacement of the papillary muscles, or deformation of the mitral annulus (7, 
21, 30).  
Based on clinical findings, MR can be acute or chronic (27). Ischemic MR is frequently chronic 
and functional. Acute ischemic MR may present due to papillary muscle infarction and rupture. 
In acute MR, there is no progressive adaptation of the left atrium to the sudden volume overload. 
This leads to a rapid increase of the left atrial and pulmonary venous pressure and results in 
acute pulmonary edema (21).  
The chronic form of ischemic MR usually occurs more than one week after myocardial 
infarction with LV wall motion abnormalities. In chronic MR, the left atrium adapts to the 
persistent volume overload. Due to prolonged volume overload, the left ventricle may over time 
dilate and lose contractile efficiency, which may lead to MV annulus dilatation and result in 
chronic heart failure (21). Patients with primary MR due to a leaflet pathology (myxomatous, 
rheumatic, or other) have a better long-term prognosis and should not be included in the group of 
patients with chronic IMR (27). 
 
1.4 Overview of imaging techniques 
The progress in cardiac imaging led to improvements in the scientific assessment of the 
anatomy, physiology, and pathophysiology of the MV. The valuable and defining role of 3D 
echocardiography, multi-slice computed tomography (MSCT) and cardiac magnetic resonance 
(CMR) imaging in evaluating the MV and the development and performance of transcatheter 
valvular therapies has been demonstrated (31). 
Echocardiography is the current gold standard for assessing the cardiac valves and is used as a 
first-line imaging technique to study mitral valve disease (32). The mitral valve can be evaluated 
by transesophageal echocardiography (TEE) or by transthoracic echocardiography (TTE).  It is 
cost-effective, widely accessible, offers excellent temporal resolution and in most cases delivers 
adequate information for therapy planning, particularly by providing a so-called “surgical view” 
(33). Echocardiography has several limitations, including operator dependence and poor acoustic 
window in some patients, and interference with catheters during percutaneous procedures like 
the Mitraclip intervention. Moreover, some studies have shown underestimation of the 
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volumetric parameters and overestimation of the LV ejection fraction as assessed by 
echocardiography (34). Additionally, for TEE, orotracheal intubation and general anesthesia is 
sometimes necessary (17). 
More recently, techniques such as multi-slice computed tomography (MSCT) and cardiac 
magnetic resonance (CMR) imaging are also widely used to study the mitral valve. These 
techniques can answer dedicated questions about paravalvular changes, associated aortic and 
myocardial diseases. 
Magnetic resonance imaging is a non-invasive imaging modality that does not expose the patient 
to ionizing radiation (32, 35). It is now established as the gold standard for a comprehensive 
assessment of the myocardium. It is also the reference standard for detailed non-invasive 
measurements of the left and right ventricular function and blood flow quantification (34). The 
main indication for CMR is myocarditis and cardiomyopathy, the second main indication is 
exclusion of coronary artery disease with stress tests. Advanced techniques such as T1 mapping 
and tagging of MR are widely used nowadays and significantly improve the sensitivity of CMR 
in myocardial assessments (36-38). In valves affected by stenosis or regurgitation, CMR allows 
both qualitative and quantitative assessments (35). However, there are several contraindications 
for using CMR imaging in certain patients (e.g., those with implanted devices such as a 
pacemaker, claustrophobia and arrhythmias that can affect ECG gating) (35). 
In recent years, computed tomographic angiography (CTA) has made impressive progress in 
cardiac imaging. By its widespread availability, high reproducibility and relative operator-
independence, CTA becomes useful tool in cardiac imaging (39).CTA enables volume rendering 
and other reconstruction techniques which enable a detailed visualization of the cardiovascular 
anatomy in congenital heart diseases as well as anatomical and dynamic changes in the heart 
valves. It can be used as an alternative to MRI for quantification of the LV and RV function in 
patients with contraindications for MRI or patients who are not capable of holding their breath 
for longer periods (34). The spatial resolution of CT is excellent and  is superior to the resolution 
of magnetic resonance imaging (MRI) (40).  The main established clinical application of MSCT 
in cardiac imaging is the evaluation of the coronary arteries and aorta.  The use of ECG-gated 
CT angiographies allows a simultaneous assessment of the cardiac anatomy and pathology, 
valvular morphology, coronary arteries, major arteries and, moreover, the mediastinum and the 
area surrounding the lungs (7, 41).   
Fast imaging time and  high spatial resolution of CTA, allowing for high quality 2D and 3D 
reconstructions of the mitral valve and subvalvular apparatus at any time point of the cardiac 
cycle (42). The short acquisition time (10-15 seconds) makes MSCT a useful tool for planning 
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surgical and interventional procedures for patients suffering from high-grade dyspnea (6, 43, 
44). 
The one of the  main challenges in cardiac CT is temporal resolution. It is inferior to the 
temporal resolution of MRI and echocardiography.  Improvement in spatial resolution is possible 
by using of second and third generation dual source MDCT technology. A modern dual-source 
scanner gives twice as good temporal resolution because data reconstruction is possible with 
only 90 tube rotation and can yield a temporal resolution less than 80 ms (45). The need for high 
temporal resolution in cardiac CT requires a low pitch, which increases radiation dose. The use 
of ionizing radiation is another  limitation of CTA in valve assessment. Retrospective ECG-
gated CT angiography is essential for obtaining cine images despite its association with a higher 
radiation exposure. Nowadays, techniques such as ECG-triggered CTA with radiation dose 
modulation are widely used and offer optimal visualization of the desired cardiac phase with a 
reduced dose in other parts of the cardiac cycle (35). Visualization of thin leaflets and chordae 
tendineae is limited by CTA (17). Moreover, CTA does not provide a direct measure of the 
valvular pressure gradient, which could be considered another limitation (35).  
 
1.5 MR treatment options 
The choice of the best treatment for patients with MR is very important. The purpose of medical 
and/or surgical therapy are to amend heart failure symptoms and to improve both LV remodeling 
and function, as well as the outcome (46). Standard conservative treatment options are optimal 
medical therapy (OMT) and cardiac resynchronization therapy (CRT) (47, 48). Pharmacotherapy 
(e.g. diuretics, vasodilators, etc.) aims to prevent organic diseases (49). CRT is the recent 
advancement in heart failure (HF) treatment. As shown by multiple randomized trials, there are 
outstanding clinical benefits associated with the use of CRT as a treatment method for selected 
patients with chronic HF (48, 50, 51). Surgical repair or replacement are the pillars of therapy 
for mitral regurgitation (MR) whenever conservative strategies fail to improve the symptoms and 
the severity increases (52). According to Kang et al. early surgery is associated with a significant 
long-term reduction of cardiac mortality and cardiac events in asymptomatic patients with severe 
MR, compared to conservative management (53). Minimally invasive surgical procedures (e.g. 
right minithoracotomy approaches, etc.) were developed to decrease patients’ morbidity and 
postoperative complications (54, 55). 
DMR is the most common form of MR referred for surgical correction. Surgical intervention for 
degenerative MR includes multiple techniques, such as leaflet repair with resection, chordal 
transfer, use of polytetrafluoroethylene neochordae, prosthetic ring or band annuloplasty and 
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mid-late systolic clicks (56). Patients with FMR universally have left ventricular dysfunction; 
they frequently suffer from concomitant heart failure and have a poorer prognosis than those 
with DMR. Unlike for DMR, surgical correction has not become the standard of care of FMR. 
Patients with FMR generally have an increased higher surgical risk, and although surgical 
correction of FMR has been shown to improve the functional class and left ventricular 
remodeling, a survival benefit has not been demonstrated (57, 58). 
Several recent papers show poor mid- and long-term results of surgical MV repair and 
replacement in patients with FMR and a severely reduced left ventricular ejection fraction (23, 
59-61). The results reported by Acker et al. (59) showed no significant differences in mortality at 
30 days or 12 months between mitral repair and mitral replacement groups. The observed 30-day 
death rates reported by the Acker group (1.6% in the repair group and 4.0% in the replacement 
group) were lower than the national rates reported by the Society of Thoracic Surgeons (5.3% 
and 8.5% for repair and replacement with CABG, respectively) (59). Restrictive annuloplasty is 
the most commonly adopted surgical procedure that improves heart failure symptoms in patients 
with chronic ischemic MR (46). A major limitation of current surgical annuloplasty techniques is 
that moderate or severe MR recurs in up to one-third of treated patients within one year of 
surgery (23, 62). Long aortic cross-clamping and cardiopulmonary bypass (CPB) have an 
independent impact on mortality risk. This has to be kept in mind when selecting the appropriate 
procedure based on the patient’s status (63).  
The number of patients with ischemic heart disease or cardiomyopathies which lead to FMR 
increases with advancing age, such that FMR is more frequent than organic MV disorders (47).    
Chronic functional/ischemic mitral regurgitation is associated with poor long-term survival (27). 
Hence, in patients with an unacceptably high surgical risk (e.g. those with significant 
comorbidities), innovative transcatheter concepts (minimally invasive procedures) may be a 
viable option.   
Minimally invasive methods for treating MR currently include transcatheter leaflet repair 
(MitraClip [Abbott Vascular, Santa Clara, CA], Mobius [Edwards Life Sciences, Irving, 
California] etc.), chordal implantation using the NeoChord device  (NeoChord, Inc, Eden Prairie, 
MN), annular shape changes approaches (indirect and direct percutaneous annuloplasty 
techniques), left ventricular reshaping using iCoapsys (Myocor, Maple Grove, MN, USA) or 
BACE devices (Mardil, Inc., Morrisville, North Carolina), and transcatheter mitral valve 
replacement. Among the current percutaneous treatment options, edge-to-edge MV repair, e.g. 
using the MitraClip procedure, is widely adopted (64-66). The MitraClip is a relatively safe 
procedure that can be performed even in high surgical risk patients (23). As Answer et al. 
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reported, percutaneous MitraClip repair is effective but associated with a higher risk of residual 
MR, and should only be considered in selected patients after careful deliberation (64). The 
optimal morphological and anatomical criteria for the MitraClip are a centrally located jet (A2-
P2 scallop), absence of valve calcification and the size of the mitral valve area (>4 cm²), etc. (67, 
68).  
In patients with mitral valve areas <4.0 cm² and extensive annular and leaflet calcification, the 
MitraClip may still be considered as a therapeutic procedure if the clinical benefits outweigh the 
risks (23). 
Transcatheter mitral valve implantation (TMVI) is another minimally invasive procedure that 
does not require CPB or an aortic X clamp; however, this procedure is still in its early infancy.  
According to the 2017 ESC Guidelines, transcatheter MV repair may be considered for 
symptomatic patients with severe chronic primary MR who are at high surgical risk or are 
inoperable, and should be discussed by the Heart Team to avoid futile treatment (69).  
 
1.5.1 Transcatheter mitral valve implantation (TMVI) 
In recent years, transcatheter mitral valve implantation (TMVI) has evolved as a new therapeutic 
concept (70, 71). On the one hand, it is a brand-new method and, until now, no devices have 
been approved yet for the clinical application. On the other hand, this technique holds great 
potential as an alternative therapy for high-risk patients (71). The 2017 update of the 2014 joint 
guideline of the American College of Cardiology and American Heart Association (ACC/AHA) 
stated that transcatheter MV repair may be considered for severely symptomatic patients (NYHA 
class III or IV) with chronic severe primary MR (stage D) who present with a favorable anatomy 
for the repair procedure and a reasonable life expectancy but have a prohibitive surgical risk due 
to severe comorbidities and remain severely symptomatic despite optimal management and 
therapy of HF (72).  
Similarly to transcatheter aortic valve implantation (TAVI), patient selection is determined by 
anatomical and clinical criteria (70). To ensure an appropriate patient selection, it is crucial to 
have precise parameters of the MV annulus, subvalvular apparatus and LV volumetric data (17, 
33, 73).   
TMVI systems must be flexible in order to deal with the complex and variable anatomy, provide 
large effective orifice areas, and be able to handle high transvalvular gradients (17). There are 
different transcatheter mitral valve implantation systems that have been implanted in humans: 
CardiAQ valve system (CArdiAQ Valve Technologies, INC.); Tiara valve (Neovasc Inc., 
Richmond, Canada); FORTIS valve (Edwards Lifesciences, Irvine, CA, USA); Tendyne valve 
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(Tendyne Inc., Roseville, MN, USA); and Twelve valve (Twelve Inc., Redwood City, CA, 
USA). All of these implants have a transapical delivery (CardiAQ also transseptal) (70). The 
Sino Medical AccuFit TMVI system (Sino Medical Sciences Technology, INC.) also offers a 
transapical delivery and shows a successful device delivery in animal studies; however, it is 
currently available only in one size (74). The Medtronic transcatheter mitral valve implantation 
system was studied in animals. This device is delivered via the transatrial approach using a right 
lateral minithoracotomy. The atrial approach is intended to avoid trauma to the left ventricle, 
which is a possible risk associated with the transapical approach. The transseptal system is 
currently in development (75).   
Each of the systems mentioned above offers new design solutions to overcome the complex 
anatomy of the MV apparatus. Considering the complexity of the structure and function of the 
mitral valve in comparison with the aortic valve, transcatheter mitral therapies still face many 
barriers. To date, there are many ongoing studies on TMVI systems (70, 74-79). Sophisticated 
imaging will play a decisive role in transcatheter mitral valve procedures.  
It remains unclear which parameters will be relevant for the planning of these procedures. 
Another challenge in TMVI is the more complex morphology and movement of the mitral valve, 
especially the mitral annulus, compared to the aortic valve and aortic root. Therefore, the 
experience gained in transcatheter therapies of the aortic valve cannot be transferred one-to-one 
to the mitral space. 
 
 
2 STUDY OBJECTIVES 
  
The goals of this study are a comprehensive assessment of the geometric and anatomical changes 
of the MV and subvalvular apparatus, the spatial relationships and mobility of the MV in 
multiple cardiac phases by MSCT in healthy subjects and in patients with FMR, identifying 
basic differences between groups and sizing strategies in regards of optimizing  the planning of 







3 MATERIALS AND METHODS 
 
3.1. Study population  
A total of 46 patients referred to the German Heart Center Berlin for a CTA were retrospectively 
studied. The study population was divided into two groups; the first group consisted of healthy 
subjects and the second group of patients with FMR. First group (control group) consists of 
patients with no known cardiac abnormality, no history of any cardiac disease, cardiac surgery or 
intervention. They had some CAD risk factors such as dyslipidaemia, hypertension, 
 smoking or positive family history. In these patients it was not possible to exclude CAD by 
clinical assessment alone and they were referred to coronary CTA. CAD was excluded in all 
patients in control group. Normal coronary arteries, normal LV volumetric parameters and no 
LV wall motion abnormalities were reported on their CT exams. Therefore, we believe that the 
current study population can be, to some extent, a representative sample of normal controls.  
In the second group we included patients with FMR because they are much more frequent 
candidates for minimally invasive procedures. The cardiac CT was performed successfully for 
both groups between 05 January 2007 and 22 January 2016. All collected data were 
retrospectively analyzed.  
This research was approved by the local ethics committee (number EA4/095/18) and was carried 
out in accordance with institutional guidelines. 
 
3.2. CT protocol for data acquisition  
All patients underwent contrast-enhanced ECG-synchronized cardiac scanning using first- or 
second-generation dual-source (2x128-slice) scanners (Somatom Definition, Somatom 
Definition Flash, Siemens AG, Erlangen, Germany) with retrospective ECG triggering to obtain 
images in all phases of the cardiac cycle (10% phases of the RR interval). CTA was successfully 
performed in all patients without any reported side effects. Prior to the CT data acquisition, beta-
blockers were administered orally or intravenously to some patients to lower the heart rate to 65-
70 bpm. This helped improve the image quality by reducing the number of artifacts related to 
cardiac motion. The study protocol was as follows: tube voltage 100-120 kV, tube current 320 
ref. mAs/rotation, rotation time 280 ms (automatic modulation), slice collimation of 128 x 
0.6 mm, temporal resolution 75 ms (not depending on the heart rate), slice width 0.75 mm, 
reconstruction increment 0.4 mm, reconstruction kernel B30f. A total of 80 to 100 ml of non-
ionic contrast medium (Imeron 400 mg/ml, Bracco, Altana Pharma, Konstanz, Germany) was 
generally administered via the antecubital / jugular vein at 4-5 ml/s, followed by saline flush (40 
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to 50 ml saline at 4-5 ml/s). Automated peak enhancement detection (bolus tracking technique) 
in the left atrium was used to time the contrast bolus with a start of the data acquisition at a 
threshold of 160 Hounsfield units. Scans were performed during an inspiration breath hold of 8 
to 10 s.  The electrocardiogram was recorded simultaneously to allow retrospective ECG 
synchronization to the cardiac cycle gating and reconstruction of the data at desired phases of the 
cardiac cycle.  
 
3.3. Data reconstruction 
The dataset was reconstructed with a slice thickness of 0.75 mm and a reconstruction increment 
of 0.4 mm, starting in early systole (0% of the cardiac cycle) all the way to the end-diastole 
(90% of the cardiac cycle) in steps of 10% of the RR interval.  
All datasets were anonymized and transferred to a post-processing workstation for off-line data 
analysis (syngo.via, Siemens AG). 
 
3.4. Data analysis 
Post-processing of the all CT data was analyzed in various cardiac orientations in static and cine 
images. The LV volumetric analysis was carried out using dedicated CT evaluation software 
(syngo.via Circulation, Siemens AG) and applying a 3D threshold segmentation algorithm. The 
end-diastole and end-systole were estimated automatically and adjusted manually if needed. 
Endocardial borders were traced semi-automatically and papillary muscles were regarded as part 
of the LV cavity (Figure 1). 
 
Figure 1. Assessment of LV endocardial and epicardial borders in four-chamber view (A), 






















The LV end-diastolic volume (LVEDV) and end-systolic volume (LVESV) were obtained; the 
left ventricular ejection fraction (LVEF) was calculated by the difference between LVESV and 
LVEDV divided by LVEDV (Figure 2).  
 
Figure 2. Exemplary table with LV volumetric parameters (A), indexed to BSA volumetric LV 
parameters (B), the graph of the cardiac cycle (C) and the AHA-conform 17-segment polar maps 

























The left ventricular measurements were performed in a long-axis MPR 2-chamber view. The LV 
long axis length was defined as the distance between the mitral annulus geometrical center and 
























Figure 3. Measurement of LV long-axis length in a 2-chamber view, reformatted images in 
diastole (A) and systole (B). 
 
The systolic and diastolic LV volumetric sphericity index (SI) was calculated on the basis of the 
end-diastolic and end-systolic LV volume and LV long-axis length in a 2-chamber view 
according to the empirical formula (80): 
SI = LV volume/LV long axis
3
× π/ 6. 
 
The left atrial (LA) volume was measured by tracing the LA cavity area in end-systolic 2-
chamber view (A1) and 4-chamber view (A2) reconstructions (Figure 4); the LA length (L) was 






































All parameters obtained were indexed to the body surface area (BSA). 
All data were anonymized and transferred to a personal computer with the 3mensio structural 
heart software loaded on the desktop for a post-processing analysis of the MV complex. The 
3mensio structural heart software package (8.0 module; Pie Medical Imaging, Netherlands) 
offers a dedicated workflow for mitral analysis by providing double-oblique multi-planar (MPR) 
and 3D reconstructions (82). 
Using this software, a double-oblique MPR is computed such that two views are displayed. The 
mitral annulus was located on the short-axis MPR views by placing a landmark point. A second 
landmark was placed near the apex of the LV on the long-axis MPR view. By placing these two 
landmarks, the LV line was defined and adjusted if needed. To trace the mitral annulus, the long-
axis MPR slices were rotated around the mitral-valve-to-apex axis and a view to start selecting 
the annulus was chosen. 16 data points were manually placed along the contour of the fibrous 
continuity while rotating the long-axis view by 22.5° in a stepwise fashion aligned to the left 
ventricular long axis. Each time a data point was placed, the long axis made a standard rotation, 
thus making it easier to place the next data point. After an initial segmentation of the saddle-
























needed. The lateral and medial fibrous trigones were manually identified using the short- and 
long-axis views by scrolling through the images to obtain the most precise lateral and medial 
points of the attachment of the anterior leaflet. After finalizing the segmentation, parameters for 
the saddle-shaped annulus were derived automatically. The mitral annulus had a calculated 
center and two color-coded segments which were used to indicate the anterior and posterior side 
of the annulus. The trigones define the border between the anterior peak and posterior 
circumference (Figure 5). 
 




The saddle-shaped annulus includes the aortomitral continuity, whereas the D-shaped annulus is 
defined by being limited anteriorly by the trigone-to trigone distance, excluding the aortomitral 
continuity.  
The annulus surface of the saddle-shaped annulus (As) is the area calculated when the annulus is 
projected to a plane perpendicular through the mathematical center of the annulus. The 3D 
perimeter of the saddle-shaped annulus (3D-Ps) is the entire circumference of the annulus as it 
exists in a 3D space. The 2D perimeter of the saddle-shaped annulus (2D-Ps) is the length of the 
annulus as it exists when projected to a plane perpendicular to the mathematical center. A virtual 
line connects the two trigones and is referred to as the trigone-to-trigone (TT) distance 
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(Figure 6). The septal-lateral (SL) distance for the saddle-shaped MV was defined as the 
projected distance from the aortic peak to the posterior peak. 
The anterior and posterior 3D and 2D perimeters of the saddle-shaped annulus represent the 
length of the anterior and posterior aspects of the mitral annulus as it exists in a 3D and 2D 
space, respectively. 
 
Figure 6. Saddle-shaped MV annular 3D segmentation and parameters in systole; the red line 
represents the posterior 3D perimeter; the white line represents the anterior 3D perimeter; the 
pink and green dots are trigones; the yellow line between them represents the TT distance. Short-

























The annular height of the saddle-shaped annulus (Hs) was measured as the perpendicular 
distance between the highest peak and the lowest nadir of the 3D contour to the least squares 
plane. An example is given in Figure 7. 
 
 
#Figure 7. Saddle-shaped mitral annulus height measurement using 3mensio software. 2-chamber 
view reformatted image of the MV saddle-shaped annulus region (A); volume-rendered image of 
the MA (B); schematic views of the nonplanar saddle-shaped mitral annulus (C and D).  
The red line represents the posterior 3D perimeter; the white line represents the anterior 3D 









































There is an automatic technique to unsaddle the anatomical mitral annulus. The anterior margin 
of the annulus for the D-shaped MV annulus was defined by the TT distance. The 3D perimeter 
(3D-Pd) is an annular circumference which is computed for the D-shaped annulus as the sum of 
the TT distance and the 3D circumference of the posterior aspect of the annulus. The 2D 
perimeter (2D-Pd) is the sum of the TT distance and the 2D circumference of the posterior 
aspect. The septal-lateral (SL) distance of the D-shaped annulus is a projected distance from the 
TT line to the posterior peak. An example of a D-shaped MA is shown in Figure 8. 
 
Figure 8. Representative example of a D-shaped mitral annulus assessment. 
 
The aorto-mitral angle is the angle between the MA trajectory and the LVOT long axis. It was 
measured automatically after defining the location of the aortic valve annulus by using markers 
identifying the nadirs of the three leaflets of the aortic valve (Figures 9, 10) 
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Figure 9. Aortic root 3 nadirs defined using the 3mensio software. 
   
 
Figure 10. Measurement of the aorto-mitral angle. Multiplanar reformatted and volume-
rendered images. Aortic nadirs in the short-axis aortic annulus view (A); aorto-mitral angle in a 



































The LA-to-LV axis angle was defined using 3-chamber-view images in systole by manually 
placing the angle tool between them (Figure 11). 
 
Figure 11.  3-chamber view reformatted 
image with angle tool for measuring the 















The respective distances from the annulus to the anterior and posterior papillary muscles were 
defined in systole and diastole. There were measured by placing 3D markers on the head of the 
anterior and posterior papillary muscles nearest to the annulus and by defining the three-
dimensional linear distance between the annulus and the actual 3D marker. The entire analysis 
took approximately one hour per patient (about 5 minutes for the assessment of each cardiac 
phase). Obtaining MV parameters and segmentation of the mitral annulus were successful in all 
subjects in all cardiac phases, despite the use of a radiation dose-reduction CT protocol. Most of 
the parameters were defined in all ten phases of the cardiac cycle to enable a dynamic 
assessment of the mitral valve. This minimum of measurements offers a detailed analysis of the 
size of the mitral apparatus, MV geometry, dynamics and mobility. The severity of 
corresponding mitral regurgitation in FMR group of patients was estimated by echocardiography 
prior to the CTA. 
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3.5. Statistical analysis 
 
All data were analyzed using the statistical software IBM SPSS Statistics, Version 22 (Armonk, 
NY, IBM Corp.). Continuous variables were expressed as means ± SD (standard deviations) and 
categorical variables as frequencies and percentages. The Kolmogorov-Smirnoff test was used to 
test for a normal distribution of continuous variables. The Shapiro-Wilk Test was used to test for 
a normal distribution. The T-test was used to compare means for normally distributed variables. 
The Wilcoxon test was used to assess variables that did not exhibit a normal distribution 







4.1 Baseline characteristics 
All parameters were analyzed for a total of 46 subjects who were divided into a control group 
(defined as healthy subjects; n=24) and an FMR group (n=22) as outlined in the study population 
section above. All patients in the FMR group had mitral valve regurgitation classified at least as 
grade II (by prior echocardiography). The first group consisted of 24 healthy subjects (18 male, 
6 females; 47 ± 11 years; range: 24-70 years) who were referred for a CTA for coronary 
assessment. Coronary disease was excluded by CTA. The healthy subjects had no history of any 
cardiac disease, cardiac surgery or intervention. All of them had normal LV volumetric 
parameters, normal LV sphericity index and no LV wall motion abnormalities.  Healthy subjects 
had not undergone prior cardiac surgery or intervention. The mean BMI for the first group was 
26 ± 2.8 kg/m². The mean LVEF was 72 ± 6%. The second group consisted of 22 patients with 
FMR (15 male, 7 female; 63 ± 7 years; range: 50-75 years, BMI 26 ± 3.5 kg/m², LVEF 31 ± 
9%). 







Table 1. Baseline characteristics and volumetric parameters of the study population 
Variable Group 1 (n=24) Group (n=22) P-value 
Age, years 47 ± 11 63 ± 7 <0.0001 
Gender, M/F 18/6 15/7 n/a 
BMI, kg/m² 26 ± 2.8 26 ± 3.5 1 
LVEDD, mm 55.2 ± 5.6 81± 11.2 <0.0001 
LVEDV, ml 138.6±25.6 313.7±100.8 <0.0001 
LVESV, ml 40.5±15.2 222.4±92.4 <0.0001 
SV, ml 97.8±16. 7 91.3±22 0.2627 
LVEF, % 71.5±5.8 31.2±9.3 <0.0001 
LVEDVI, ml/qm 70.5±10.9 161.8±47.5 <0.0001 
LVESVI, ml/qm 20.2±5.9 108±48.5 <0.0001 
SVI, ml/qm 50.4±7.9 47.5±10.3 0.2874 
CO, l/min 7.2±1.5 6.7±2 0.3401 
CI, l/min/qm 3.7±0.8 3.5±0.9 0.4292 
LV-sphericity index, systole 0.2±0.08 0.4±0.1 <0.0001 
LV-sphericity index, diastole 0.3±0.07 0.5±0.1 <0.0001 
LA volume, end systole, ml 79.9±18.9 157.2±46.6 <0.0001 
LA volume index, ml/qm 41±9.9 81±19.8 <0.0001 
BMI = body mass index; LVEDD = end-diastolic diameter of LV; LVEDV / LVESV = left 
ventricular end-diastolic / systolic volume; SV = stroke volume; LVEF = LV ejection fraction; 
LVEDVI, LVESVI = left ventricular end-diastolic / systolic volume index; SVI = stroke 
volume index; CO = cardiac output; CI = cardiac index; LA = left atrium. 
Values are expressed as the mean ± SD. M indicates male, F indicates female. 
 
4.2 Systolic and diastolic LV sphericity index 
Measurements of the LV volumetric sphericity index (SI) showed a significant difference 
between the two groups. The mean diastolic LV volumetric sphericity index (SI) is 0.3 ± 0.07 
versus 0.5 ± 0.09 in diastole and 0.16 ± 0.08 versus 0.44 ± 0.1 in systole (P <0.05) with no 




Figure 12. LV sphericity index values in diastole (a) and in systole (b) for both groups 
                       Fig. 12a.                                                                       Fig. 12b. 
 
4.3 Mitral annulus dimensions  
 
The annular contours were successfully segmented in all patients. All annulus parameters are 
expressed as means calculated from the values of the MV parameters in all subjects in each 
group and were averaged over all 10% phases of the cardiac cycle. 
The average mean area of the mitral valve (annulus surface) in FMR patients for saddle-shaped 
and D-shaped models was 14.6 ± 0.52 cm² and 12.7 ± 0.49 cm², respectively, and was found to 
be higher than those of the control group  (12.1 ± 2.2 cm² vs. 10.3 ± 1.6 cm²). The average mean 
3D perimeter (the entire circumference of the annulus as it exists in a 3D space) of the saddle-
shaped annulus (3D-Ps) was 130.8 ± 10.8 mm vs. 143 ±2.7 mm in Group 1 and Group 2, 
respectively. The 2D perimeter of the saddle-shaped annulus (2D-Ps) was also greater in 
Group 2 compared to healthy subjects (136.7 ±2.4 mm [Group 2] vs. 124.8 ± 10.3 mm 
[Group 1]). The 3D and 2D perimeters of the D-shaped MA values were without a significant 
difference between both groups and with minor differences between the 3D and 2D values in the 
FMR group (121.5 ± 8.1 mm vs. 132.5 ± 2.7 mm for 3D-Pd, and 119.9 ± 9.1 mm vs. 131.2 ± 
2.5 mm for 2D-Pd). 
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The difference between the trigone-to trigone (TT) distance between the two groups was not 
pronounced and was 33.7 ± 1.9 mm in the control group and 34.6 ± 1.4 mm in the FMR group. 
The septal-lateral (SL) distance for the saddle-shaped MV was defined as 36.64 ± 5.7 mm for 
Group 1 and 43 ± 1.3 mm for Group 2. The septal-lateral (SL) distance for the D-shaped MV 
was defined as 29.3 ± 5.7 mm for Group 1 and 34.7 ± 1.4 mm for Group 2. 
4.3.1 Mitral annulus dimensions in the saddle-shaped model 
The saddle-shaped MA dimensions, including annulus surface, entire circumference, projected 
circumference etc., were generally found to be significantly larger in the FMR group compared 
to the healthy subjects. Tables 2-7 contain a summary of annulus surface (As), projected 
circumference of the entire saddle-shaped annulus (2D-Ps), entire anterior circumference (3D-Ps 
anterior), entire posterior circumference (3D-Ps posterior), projected distance from the aortic 
peak to the posterior peak (SLs), projected anterior circumference (2D-Ps anterior), projected 
posterior circumference (2D-Ps posterior) and annular height (Hs). The fluctuation in MA 
dimensions throughout the cardiac cycle was found to be significantly higher in Group 1 
(healthy subjects) than in Group 2. 
The graph showing the mean values of the mitral annulus entire circumference for the saddle-
shaped annulus model is a good example of minor changes in the MA dimensions during the 
cardiac cycle in the FMR group (Figure 13). Difference in the mitral annulus height for the 
saddle-shaped annulus (Hs) and fluctuations thereof during the cardiac cycle is shown on 
another graph (Figure 14). 
 
Table 2. Annulus surface (As) values in the S-shaped mitral annulus model for both groups 
Annulus surface (As) 
Group 1 Group 2  
Mean SDV Mean SDV p-value 
Mitral valve saddle-shaped 
annulus surface, cm² 0% 
10.50 1.98 14.32 2.12 <0.0001 
Mitral valve saddle-shaped 
annulus surface, cm² 10% 
11.48 1.69 14.66 2.22 <0.0001 
Mitral valve saddle-shaped 
annulus surface, cm² 20% 
12.53 1.84 14.73 2.39 0.001 
Mitral valve saddle-shaped 
annulus surface, cm² 30% 
12.61 2.12 14.84 2.44 0.002 
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Mitral valve saddle-shaped 
annulus surface, cm² 40% 
12.51 2.08 14.54 2.25 0.003 
Mitral valve saddle-shaped 
annulus surface, cm² 50% 
12.49 1.96 14.67 2.30 0.001 
Mitral valve saddle-shaped 
annulus surface, cm² 60% 
12.39 1.79 14.51 2.15 0.001 
Mitral valve saddle-shaped 
annulus surface, cm² 70% 
12.29 1.84 14.58 2.42 0.001 
Mitral valve saddle-shaped 
annulus surface, cm² 80% 
12.45 1.72 14.65 2.20 0.001 
Mitral valve saddle-shaped 
annulus surface, cm² 90% 
11.81 2.09 14.83 2.17 <0.0001 
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Table 4. Projected circumference of the entire saddle-shaped annulus (2D-Ps) for both groups in 
all phases of the cardiac cycle 
Projected circumference of the 
entire saddle-shaped annulus 
(2D-Ps)  
Group 1 Group 2  
Mean SDV Mean SDV p-value 
2D-Ps circumference, mm, 0% 116.79 10.83 135.22 10.09 <0.0001 
2D-Ps circumference, mm, 10% 121.83 8.96 136.60 10.09 <0.0001 
2D-Ps circumference, mm, 20% 127.09 9.60 137.21 11.11 0.002 
2D-Ps circumference, mm, 30% 127.02 10.62 137.60 11.01 0.002 
2D-Ps circumference, mm, 40% 126.40 10.42 136.19 10.65 0.003 
2D-Ps circumference, mm, 50% 126.65 9.71 136.90 10.69 0.002 
2D-Ps circumference, mm, 60% 126.49 8.88 136.36 9.93 0.001 
2D-Ps circumference, mm, 70% 126.12 9.18 136.53 11.38 0.002 
2D-Ps circumference, mm, 80% 126.68 8.68 136.93 9.98 0.001 
2D-Ps circumference, mm, 90% 123.42 10.91 137.39 9.86 <0.0001 
 
Table 5. Summary of the projected distance from the aortic peak to the posterior peak (SLs) 
Projected distance from the 
aortic peak to the posterior peak 
(SLs) 
Group 1 Group 2  
Mean SDV Mean SDV p-value 
SL from the aortic peak to the 
posterior peak, 0% 
32.89 3.09 42.63 3.66 <0.0001 
SL from the aortic peak to the 
posterior peak, 10% 
34.83 2.94 42.12 4.22 <0.0001 
SL from the aortic peak to the 
posterior peak, 20% 
37.36 3.04 42.84 4.16 <0.0001 
SL from the aortic peak to the 
posterior peak, 30% 
37.93 2.86 43.11 3.87 <0.0001 
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SL from the aortic peak to the 
posterior peak, 40% 
38.60 2.98 43.42 3.48 <0.0001 
SL from the aortic peak to the 
posterior peak, 50% 
37.97 3.36 42.91 3.91 <0.0001 
SL from the aortic peak to the 
posterior peak, 60% 
37.53 3.25 43.35 3.67 <0.0001 
SL from the aortic peak to the 
posterior peak, 70% 
37.23 2.80 43.30 4.29 <0.0001 
SL from the aortic peak to the 
posterior peak, 80% 
37.03 2.68 43.29 3.47 <0.0001 
SL from the aortic peak to the 
posterior peak, 90% 
35.03 3.42 43.26 3.76 <0.0001 
 
Table 6. Summary of the entire anterior circumference (3D-Ps anterior) of the MA for both 
groups 
Entire anterior circumference 
(3D-Ps anterior) 
Group 1 Group 2  
Mean SDV Mean SDV p-value 
3D-Ps anterior, mm, 0% 41.25 4.61 44.55 4.32 0.02 
3D-Ps anterior, mm, 10% 43.33 4.57 45.23 3.79 0.13 
3D-Ps anterior, mm, 20% 43.83 3.51 46.64 4.69 0.03 
3D-Ps anterior, mm, 30% 44.54 4.92 46.55 6.15 0.23 
3D-Ps anterior, mm, 40% 44.42 5.69 45.32 5.47 0.59 
3D-Ps anterior, mm, 50% 44.00 4.11 44.45 5.30 0.75 
3D-Ps anterior, mm, 60% 43.75 4.53 45.32 5.76 0.31 
3D-Ps anterior, mm, 70% 43.83 4.31 50.77 16.79 0.07 
3D-Ps anterior, mm, 80% 44.58 5.44 44.77 3.68 0.89 
3D-Ps anterior, mm, 90% 41.88 3,5547 43.50 9.07 0.18 
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Table 7. Summary of the entire posterior circumference (3D-Ps posterior) of the MA for both 
groups 
Entire posterior circumference 
(3D-Ps posterior)  
Group 1 Group 2  
Mean SDV Mean SDV p-value 
3D-Ps posterior, mm,0% 82.88 8.65 98.05 8.38 <0.0001 
3D-Ps posterior, mm, 10% 86.71 7.69 98.45 9.00 <0.0001 
3D-Ps posterior, mm, 20% 90.08 8.89 98.14 9.67 0.005 
3D-Ps posterior, mm, 30% 89.50 9.66 93.00 20.38 0.469 
3D-Ps posterior, mm, 40% 89.08 9.26 97.23 9.82 0.006 
3D-Ps posterior, mm, 50% 89.00 7.98 97.50 10.00 0.003 
3D-Ps posterior, mm, 60% 90.21 9.18 97.55 9.09 0.009 
3D-Ps posterior, mm, 70% 88.29 7.30 91.95 20.22 0.429 
3D-Ps posterior, mm, 80% 89.13 6.92 97.77 9.45 0.001 
3D-Ps posterior, mm, 90% 87.79 8.99 99.68 9.00 <0.0001 
 
 
Table 8. Summary of the projected anterior circumference (2D-Ps anterior) of the MA 
Projected anterior 
circumference (2D – Ps 
anterior)  
Group 1 Group 2  
Mean SDV Mean SDV p-value 
2D-Ps anterior, mm, 0% 36.67 4.15 39.00 4.05 0.005 
2D-Ps anterior, mm, 10% 37.92 4.19 40.14 3.24 <0.0001 
2D-Ps anterior, mm, 20% 38.96 3.25 41.14 3.55 0.006 
2D-Ps anterior, mm, 30% 39.63 4.66 42.09 5.10 0.003 
2D-Ps anterior, mm, 40% 39.63 4.35 40.73 4.28 0.005 
2D-Ps anterior, mm, 50% 39.79 3.45 41.00 4.20 0.002 
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2D-Psanterior, mm, 60% 38.63 3.27 40.59 4.34 0.003 
2D-Ps anterior, mm, 70% 39.67 3.74 46.00 17.90 0.263 
2D-Ps anterior, mm, 80% 39.46 3.54 41.18 3.70 0.001 




Table 9. Projected posterior circumference (2D-Ps posterior) for both groups 
Projected posterior 
circumference (2D-Ps posterior) 
Group 1 Group 2  
Mean SDV Mean SDV p-value 
2D-Ps posterior, mm,0% 80.00 7.95 96.14 8.15 0.06 
2D-Ps posterior, mm, 10% 83.92 8.22 96.50 8.94 0.05 
2D-Ps posterior, mm, 20% 88.17 8.97 95.95 9.43 0.04 
2D-Ps posterior, mm, 30% 87.38 9.41 95.68 8.82 0.10 
2D-Ps posterior, mm, 40% 87.13 9.40 95.55 9.90 0.39 
2D-Ps posterior, mm, 50% 87.08 7.78 95.77 9.67 0.29 
2D-Ps posterior, mm, 60% 87.88 8.08 95.68 8.85 0.09 
2D-Ps posterior, mm, 70% 86.33 7.70 91.08 18.05 0.12 
2D-Ps posterior, mm, 80% 87.29 7.15 96.23 9.31 0.11 
2D-Ps posterior, mm, 90% 85.29 8.79 97.91 8.71 0.18 
 
The annular height values in the saddle-shaped MA ( were found to be not significantly different 
between the two groups, however there were fluctuations throughout the entire cardiac cycle for 
both groups. 
The minimal and maximal annular height values (saddle-shaped model) in the first group were 
9.99 ± 1.33 and 11.30 ± 1.74 and in the second group 10.24 ± 1.40 and 11.42 ± 2.35, 
respectively (Table 10). 
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Figure 14. Difference in the mitral annulus height for the saddle-shaped annulus (Hs) and 
fluctuations thereof during the cardiac cycle 
 
 
4.3.2. Mitral annulus dimensions in the D-shaped model 
The D-shaped MA dimensions, including annulus surface (Ad), entire circumference (3D-Pd), 
projected distance from the aortic peak to the posterior peak in the D-shaped mitral annulus 
model (SLd), projected circumference and anterior circumference - which was defined as the 
trigone-to-trigone (TT) distance - were generally found to be significantly smaller in the first 
group compared to the second group; this trend was steady throughout the entire cardiac cycle. 
Tables 11-13 contain a summary of the results for some of the D-shaped mitral annulus 
parameters. 
In addition, on graphs with mean values of mitral annulus entire circumference (3D-Pd) and 
projected circumference (2D-Pd) for D-shaped annulus model is obvious a continuous 
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Table 11. Summary of mitral annulus surface dimensions in the D-shaped MA model (Ad) for 
every 10% phase of the cardiac cycle 
Annulus surface (Ad) 
Group 1 Group 2  
Mean SDV Mean SDV p-value 
Mitral valve, D-shaped 
annulus, Ad, cm², 0% 
9.11 1.80 12.58 1.99 <0.0001 
Mitral valve, D-shaped 
annulus, Ad, cm², 10% 
9.92 1.72 12.78 2.08 <0.0001 
Mitral valve, D-shaped 
annulus, Ad, cm², 20% 
10.75 1.87 12.74 2.24 <0.0001 
Mitral valve, D-shaped 
annulus, Ad, cm², 30% 
10.71 2.12 12.67 2.20 0.004 
Mitral valve, D-shaped 
annulus, Ad, cm², 40% 
10.63 2.03 12.51 2.34 0.006 
Mitral valve, D-shaped 
annulus, Ad, cm², 50% 
10.65 1.82 12.62 2.27 0.002 
Mitral valve, D-shaped 
annulus, Ad, cm², 60% 
10.70 1.88 12.59 2.08 0.003 
Mitral valve, D-shaped 
annulus, Ad, cm², 70% 
10.51 1.80 12.65 2.37 0.001 
Mitral valve, D-shaped 
annulus, Ad, cm², 80% 
10.71 1.65 12.71 2.27 0.002 
Mitral valve, D-shaped 
annulus, Ad, cm², 90% 









Figure 15. Summary of dimensions of the mitral annulus entire circumference of the D-shaped 
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Table 12. Projected distance from the aortic peak to the posterior peak in the D-shaped mitral 
annulus model (SLd) 
Projected distance from 
the aortic peak to the 
posterior peak in the D-
shaped mitral annulus 
model (SLd) 
Group 1 Group 2  
Mean SDV Mean SDV p-value 
SLd, mm, 0% 26.58 2.71 35.04 3.33 <0.0001 
SLd, mm, 10% 27.95 2.87 34.47 3.60 <0.0001 
SLd, mm, 20% 29.52 2.99 34.40 3.66 <0.0001 
SLd, mm, 30% 32.26 12.35 34.05 3.25 0.498 
SLd, mm, 40% 29.33 4.98 34.34 3.60 <0.0001 
SLd, mm, 50% 29.78 2.83 34.42 3.89 <0.0001 
SLd, mm, 60% 29.80 3.50 34.83 3.88 <0.0001 
SLd, mm, 70% 29.41 3.04 35.04 3.80 <0.0001 
SLd, mm, 80% 29.53 3.02 35.15 3.66 <0.0001 
SLd, mm, 90% 28.69 3.63 35.40 3.49 <0.0001 
 




Group 1 Group 2  
Mean SDV Mean SDV p-value 
TT distance, mm 0% 32.54 3.77 33.89 3.20 0.196 
TT distance, mm, 10% 33.19 2.95 34.83 2.64 0.054 
TT distance, mm, 20% 33.64 2.69 35.09 2.80 0.082 
TT distance, mm, 30% 34.33 3.80 35.31 3.46 0.365 
TT distance, mm, 40% 33.65 3.21 34.10 3.14 0.630 
TT distance, mm, 50% 34.05 3.24 34.84 3.24 0.413 
TT distance, mm, 60% 33.24 2.72 34.72 3.48 0.118 
TT distance, mm, 70% 34.14 3.32 34.07 3.43 0.942 
TT distance, mm, 80% 34.44 3.17 34.67 3.17 0.803 
TT distance, mm, 90% 34.01 3.09 34.31 3.31 0.748 
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4.3.2 Comparison of the two mitral annulus models and between the 2D and 3D dimensions 
When comparing the two mitral annulus models, parameters including the annulus area, 3D and 
2D perimeter (especially the anterior one) and the SL distance values were larger for the saddle-
shaped model due to including the aorto-mitral continuity. This tendency is similar in both 
groups, but shows a large gap in the range in Group 1. For the saddle-shaped annulus the 
average mean area throughout the cardiac cycle was 12.1 ± 2.1 cm² (range: 10.5-12.61) for the 
control group and 14.6 ± 0.52 cm² (range: 14.32-14.84) for the FMR patients. Compared to the 
area of the D-shaped annulus (10.3 ± 1.6 cm² (range: 9.4-10.8) vs. 12.7 ± 0.5 cm² (range: 12.5-
13), respectively, the average mean area of the saddle-shaped annulus was thus considerably 
larger. The discrepancy between the mean 3D circumferences of the saddle-shaped and the D-
shaped model is more pronounced than in 2D circumference values of both MA models. The 3D 
perimeter of the saddle-shaped annulus (3D-Ps) was 130.8 ± 10.8 mm (range: 123.3-134.1) in 
Group 1 vs. 143 ± 2.7 mm (range: 142.1-144.9) in Group 2. The 3D perimeter of the D-shaped 
annulus in Group 1 was 121.5 ± 8.1 mm (range: 115.5-123.6) vs. 132.5 ± 2.7 mm (range: 131.3-
133.98) in Group 2. The 2D-Ps was 124.8 ± 10.3 mm (range: 116.8-127.1) in healthy subjects 
vs. 136.7 ±2.4 mm (range: 135.2-137.6) in FMR patients. The 2D-Pd values were 119.9 ± 
9.1 mm (range: 113.4-122.5) vs. 131.2 ± 2.5 mm (range: 130-132.5) for Groups 1 and 2, 
respectively. Likewise, there was notable difference between the anterior 3D and 2D perimeter 
of the saddle-shaped annulus values, whereas there were only slight changes between them in 
D-shaped model and minor changes between the 3D and 2D posterior perimeter values in both 
models. The anterior 3D perimeter of the saddle-shaped annulus for both groups was 43.5 ± 
3.3 mm vs. 45.7 ± 7.3 mm, and the posterior 3D perimeter was 88.3 ± 7.3 mm vs. 96.9 ± 
7.7 mm, respectively. The anterior 2D perimeter of the saddle-shaped annulus for both groups 
was 28.5 ± 3.1 mm vs. 41.1 ± 7 mm, and the posterior 2D perimeter was 86 ± 8.1 mm vs. 95.6 ± 
6.8 mm, respectively. Compared with the D-shaped model, the SL distance in the saddle-shaped 
model was significantly longer (mean SLs 36.6 ± 5.7 mm [range: 32.9-38.6] in the control group 
and 43 ± 1.3 mm [range: 42.1-43.4] in the FMR group; mean SLd 29.3 ± 5.7 mm [range: 26.6-
32.3] in Group 1 and 34.7 ± 1.35 mm [range: 34-35.4] in Group 2). The mean TT distance 
remained constant for both MA models. As the above values clearly show, the differences in the 
3D and 2D entire perimeter, the anterior and posterior circumference and the SL distance were 
more pronounced in the saddle-shaped model and not very significant in the D-shaped model. 
Moreover, the gap between the 3D and 2D parameters for both MA assessment models is greater 
in Group 1 than in Group 2.  
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4.3.3. Comparison of MA parameters in systole and diastole between the two groups 
There were statistically significant differences in mitral annulus dimensions, MA to papillary 
muscle distances and other parameters in systole and diastole between the healthy subjects and 
the FMR group (Figure 17). Most of the parameters were higher in the second group compared 
to the healthy subjects. For example, the saddle-shaped annulus area in systole was 12.575 ± 
2 cm² vs. 14.732 ± 2.5 cm² and in diastole 11.646 ± 2.2 cm² vs. 14.655 ± 2.3 cm² for Groups 1 
and 2, respectively. However, the gap between most of the values in systole and diastole is 
greater in Group 1 than in Group 2, where the difference between the values in systole and 
diastole is not as pronounced. 
 
Figure 17. Mean values of MA dimensions for saddle-shaped and D- shaped approaches in 





































Group 1 systole Group 1 diastole Group 2 systole Group 2 diastole
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4.4 Aorto-mitral angle 
The aorto-mitral angle was measured for the saddle shaped MV annulus in every 10% phase of 
the cardiac cycle. The measurements values were higher in the healthy group and this pattern 
remained consistent through the entire cardiac cycle. This means that the aorto-mitral angle was 
steeper in Group 2. The maximal mean aorto-mitral angle degree value in the first group was 
58.5  ± 5.91 (P < 0.001) in 40% phase of cardiac cycle  and minimal mean value was 51.59 ± 
6.22 (P 0.001) in 90% phase of cardiac cycle.  In the second group the maximal and minimal 
mean aorto-mitral angle degree value were 48.94 ± 7.07 (in 50% phase of cardiac cycle) and 
42.16 ± 7.22 (in 0% phase of cardiac cycle), respectively. A difference of AMAA values for 
both groups is illustrated in Figure 18. 
 
Figure 18. Mean values of the aorto-mitral angle for both groups. 
 
4.5 Annulus to papillary muscles distances  
The distances for the mitral annulus to the anterior and posterior papillary muscle heads were 
measured in systole and diastole in all subjects and averaged ≥20 mm. 
The difference in the distance between the MV annulus and the anterior papillary muscle is 
evident between the two groups. The mean annulus to anterior PM distance in systole was 22.7 ± 
3.9 mm in the first group and 19.8 ± 3.2 mm in the second group (p-value 0.0207) and, in 
diastole, 24.6 ± 4.2 mm versus 22.1 ± 3.4 mm (p-value 0.0341), respectively. There was no big 
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Based on conventional criteria, the difference in the mean distance between the mitral annulus 
and the posterior PM is considered to be not statistically significant at 23.9 ± 3.9 mm vs. 24 ± 




4.4. LA-to-LV axis angle 
The LA-to-LV angle was measured in the 3-chamber view during the systolic cardiac phase. 
No significant difference was found between the average LA-to-LV angle in the healthy subjects 
and in the patients with FMR. The mean LA-to-LV axis angle was 151 ± 6.4° (range: 138-164) 
and 157.5 ± 6.4° (range: 146-168), respectively (Figure 19). 
 
Figure 19. Difference in LA-to-LV axis angle during systole in the 3-chamber view (reformatted 


















4.5 Mitral annular dynamics (mobility of the MA) 
The mobility of the mitral annulus was defined as the difference between the minimum and 
maximum of each parameter. Means and standard deviations were calculated to compare the 
mobility. As shown in the table and exemplary graphs, the mobility of the MV annulus in 
healthy subjects is consistently higher than in second group. 
The summary of the mean values of the mobility of the mitral annulus throughout the cardiac 
cycle for the control and FMR groups are shown in Table 15 and Figures 20 and 21. 
 
Table 15. Mean values of the mitral annulus mobility (mean ±SD) 
 
Parameter 
Mean annulus mobility 
P-value 
Group 1 Group 2 
3D-mitral annular 
circumference (mm) 
17 ± 7.4 11 ± 3.9 < 0.05 
2D-mitral annular 
circumference (mm) 
15 ± 4.4 8 ± 3 < 0.001 
Trigone-to-trigone distance 
(mm) 
6 ± 1.9 5 ± 1 0.06 
Antero-posterior-distance 3D 
(SL distance) (mm) 
8 ± 2.2 5 ± 1.9 < 0.001 
Aorto-mitral annular  
angle (°) 














Figure 20. MA mobility: Anteroposterior-distances (SLs-distance 3D) for both groups in all 
cardiac cycle phases (the orange line represents the minimum for each patient, the blue line the 
maximum for each patient). 
 
 
Figure 21. MA mobility: 3D entire circumference for the saddle-shaped annulus (3D-Ps) for 
both groups in all cardiac cycle phases (the orange line represents the minimum for each patient, 
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FMR is the second most common valvular heart disease whose prevalence is expected to grow 
due to the increasing life expectancies in the industrialized nations (5). Surgical or percutaneous 
interventions are available to treat severe symptomatic FMR (59, 83). To determine the best 
treatment for the patient and to improve clinical outcomes, the best approach for a 
comprehensive pre-procedural assessment of the MV and standardization of this approach must 
be defined. For instance, knowing the precise size of the MA is very important for successful 
MV replacements: using a larger-size valve reduces the risk for displacement toward the left 
atrium due to improved anchoring to the native mitral annulus; however, oversizing increases the 
risk of LVOT obstruction (84). Different imaging modalities and MA segmentation techniques 
have been reported. Due to the heterogeneity of the results of previous studies, the 
standardization of MV evaluation remains unclear. 
 
5.1 Interpretation of the study results and their significance 
Against the backdrop of the lacking consensus on how to measure the mitral valve in regards of 
planning for minimally invasive procedures, we comprehensively analyzed the mitral apparatus, 
its anatomy, geometry, mobility, as well as the spatial relationships between its components and 
surrounding structures, such as the atrioventricular conduction axis and the aortic valve. 
The major findings of this study are: 
(1) There are significant differences in the mitral annular morphology between healthy 
subjects and patients with FMR; 
(2) When comparing the two mitral annulus models, the vast majority of parameters were 
higher for the saddle-shaped model compared to D-shaped model; 
(3) 2D and 3D assessments of the mitral annular morphology throughout the cardiac cycle 
show differences between the MA circumferences; 
(4) The more pronounced difference between the mean distance of the MA to the anterior 
papillary muscle vs. the mean distance of the MA to the posterior PM were observed in 
both groups; 
(5) The mobility of the mitral annulus is higher in healthy subjects than in patients with 
FMR. 
The results of the analysis presented here demonstrate that with good optimization of the 
procedural protocol and post-processing process, MSCT represents a feasible method for 
precisely evaluating the dimensions and mobility of the mitral valve. 
53 
In addition, in our study we included subjects with nearly the same mean BMI (≈26) as well as 
both genders in both groups to assess MV parameters more objectively for the general 
population. The number of male/female subjects in both groups was similar. 
 
5.2. Comparison of results with earlier studies 
No standardized method for assessing the mitral annulus has been defined. Although the saddle-
shaped annulus is anatomically correct, some authors included the anterior horn of the MA 
(aortomitral continuity), while others did not. It should be noted that different devices may 
require specific measurements and D-shape annulus approach does not always correspond with 
the shape of device. Considering, different shape of devices and different parameters required 
for preprocedural assessment, the entire geometric shape of the MA needs to be considered when 
assessing for neo-LVOT obstruction. Blanke et al. hypothesized that MA must be modified by 
cutting off the aorto-mitral continuity and defining the anterior border of the MA as a virtual line 
connecting both trigones (planar D-shaped annulus) for pre-procedural device sizing in terms of 
avoiding LVOT obstruction (85). The proposal of Blanke et al. D-shaped model of MA was 
further used in a study by Abdelghani et al. (86). Measurements in both studies mentioned above 
were made only in diastolic phase of cardiac cycle. Good correlation was found for the annular 
dimension for D-shaped approach values. Unlike these studies, we reported saddle-shape annular 
dimensions including the aortomitral continuity and found considerable differences between the 
data obtained in our study and in the studies mentioned above due to different saddle-shaped 
annulus assessment approaches.  
According to our data, the annulus area is considerably larger in the saddle-shaped MA model 
compared to the D-shaped model; this finding correlates closely with previous studies (44, 85, 
87) in which aorto-mitral continuity was included. Based on our results and former clinical 
reports, we thus conclude that the saddle-shaped annulus area extends to the LVOT and may 
theoretically cause obstruction thereof.  
No significant differences were ascertained regarding the average mean annular area, the 3D and 
2D perimeters and the SL distance for both the saddle-shaped and D-shaped MA evaluation 
models in our study, compared to the results published by Blanke et al. (44). We have used the 
same technique and the same software (3mensio structural heart software (Pie Medical Imaging, 
Netherlands). 
Study population in Alkadhi et al. study include control subjects, patients with cardiomyopathy 
(dilative and hypertrophic obstructive) and to assess the 3D MA area PointWrap Algorithm was 
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used (43). In comparison to our results, mean S-shaped MA area is without significant gap in 
control group and found to be bigger in patients with dilative cardiomyopathy.  
They are significantly larger gap to MA area values between our study and results reported by 
Beaudoin et al. (88). In this study the annulus area was measured only in midsystole and total 
leaflet area was measured in diastole. Dedicated software (Omni4D, MD Handschumacher) was 
used.  
In comparison to Alkadhi et al.(43) and Beaudoin et al.(88) differences in results are likely due 
to different assessment technique and different software used, since when using the same 
methodology and the same software, there is no marked difference in the results  as in 
comparison to Blanke et al. study (44). 
In agreement with a previous study of Mak et al., we found nearly similar results for the SL and 
TT distances and slightly different results for the annular area of the D-shaped mitral annulus 
mean for the FMR group in mid-diastole (87). 
Delgado and colleagues reported that the area of the MA was significantly higher in heart failure 
patients compared to the control group, thus suggesting annular dilatation (7). The present study 
reported similar results. 
Ormiston et al. reported changes in the annular area throughout the cardiac cycle as defined by 
echocardiography and measured maximum values for the annular area in late diastole and 
minimal values in mid systole already in 1981 (89). The largest mid-diastolic largest MA area 
was demonstrated later by other authors (43, 90, 91). 
According to our study, the annular height of the saddle-shaped annulus was highest in diastole 
and lowest in mid-to-late systole. This finding proves flattening of the MA in the diastolic phase, 
as reported by Alkadhi et al. (43) and Blanke et al. (33). In FMR patients the saddle-shaped 
mitral annulus height decreases in general, resulting in a more planar annular contour according 
to a recent paper by Blanke et al. Furthermore, their investigation reported a mean MA area of 
the D-shaped annulus of 8.9 ±1.5 cm² in control subjects. The mean MA area was found to be 
slightly bigger in our study (10.3 ± 1.6 cm²) (33). 
Compared to our study, Theriault-Lauzier et al. provided MA data only for the diastolic phase, 
and only half of the cohort was additionally evaluated in systole (92). Important findings 
reported by the Theriault-Lauzier group, who compared the aorto-mitral angle between patients 
with and without FMR, included slight changes in systole and a decreased angle in the FMR 
group in diastole (92). 
Our study clearly showed higher aorto-mitral annular angles in healthy subjects compared to 
patients with FMR; this picture was consistent through the cardiac cycle.  
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As part of the subvalvular assessment, the annulus-to-PM evaluation is important regarding the 
placement of the transcatheter device. It is referred to as an “obstacle-free zone” (73). We clearly 
showed a difference in the distance between the annulus and the anterior papillary muscle 
between the two groups, both in systole and in diastole, whereas the annulus-to-PM distance are 
nearly identical between the first and second group and differed only slightly between systole 
and diastole. Likewise, Theriault-Lauzier et al. showed a mild difference in the distance of the 
annulus to the anterior and posterior PM in systole and diastole; however, without distinguishing 
between the mean values of the groups with and without FMR, which was done in our study 
(92). 
Considering all the findings detailed above, we assume good reproducibility of the assessment of 
most of the MV parameters in studies that are conducted with similar techniques. 
The left atrium plays a key role in protecting the pulmonary vessels in mitral valve disease. 
Because the atrium becomes dysfunctional due to the regurgitant load, symptoms of pulmonary 
artery hypertension occur. An LA volume index > 60 ml/m² predicts an adverse cardiovascular 
outcome. In our study, the LA volume index in the FMR group was 81 ± 19.8 ml/m² vs. 41 ± 
9.9 ml/m² in healthy subjects, which is in line with results reported by Ring L. and Le Tourneau 
T. (93, 94). 
Furthermore, as an important part of the MV apparatus, in our study we also assessed LV 
hemodynamics and dimensions including LV long axis, LV sphericity index, and annulus to 
papillary muscles distances. As expected, we found pronounced higher than normal LV 
hemodynamics in the FMR group compared to the control group. 
The LV sphericity index in systole and diastole are consistent with values published by the Di 
Donato and Delgado groups (7, 80) and was found to be higher in the FMR group owing to LV 
remodeling. 
Several recent studies, such as Hulman et al. and Blanke et al., suggested using multiphase ECG-
gated CT for a pre-procedural assessment of the mitral valve to choose the correct valve size (33, 
84). Retrospective ECG-gated CTA is essential for obtaining both static and cine images. Cine 
clips obtained of each valve allow monitoring of valve motion. In our study, we also included a 
quantitative assessment of the valve mobility and compared the values measured in the control 
group and FMR group. 
Our results showed that the mobility of the mitral annulus is much lower in FMR patients. Thus, 
multiphase ECG-gated preprocedural CT may not be necessary when planning transcatheter 
mitral valve procedures. Single- or dual-phase CT scans with prospective ECG synchronization 
can provide enough data for a pre-procedural analysis in such patients. Moreover, using such a 
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protocol can reduce the radiation exposure and risks. We assume that using multiphase CTA 
may still be beneficial in complicated cases, e.g. in patients with basal septal hypertrophy or 
prior aortic investigation or other unusual clinical scenarios, in order to prevent LVOT 
obstruction and to reduce risk of prosthetic valve mismatch. 
Nonetheless, our data highlight the importance of a careful analysis with the potential to 
optimize pre-procedural exposure and reduce the dose of radiation and contrast media. 
 
5.3 The advantages of CTA in evaluating the MV and comparison with other clinical 
imaging procedures 
As stated in the previous section, it is necessary to take into account not only the mitral valvular 
apparatus when considering the relevant anatomy, but also the relationship between its 
components and the surrounding structures, such as the atrioventricular conduction axis, the 
aortic valve, the coronary sinus, and the circumflex coronary artery (5, 8). In comparison with 
echocardiography and CMR, CTA can provide such information with accurate 3D datasets of the 
cardiac morphology, excellent image quality, a higher spatial resolution and lower signal-to-
noise ratio, a higher contrast between the cardiac chamber wall and blood flow (85, 87).  
Quantitative values relating to the LV function and muscle mass are independent predictors of 
cardiac morbidity and mortality. Hence, an accurate analysis of LV volumetric data is also very 
important and made possible by CTA. The data obtained by ECG-gated CTA is very 
comprehensive and may suffice for a pre-procedural analysis (88). At present, CT offers the 
highest 3D spatial resolution of all techniques (14). By performing MSCT for MV assessment, 
any findings which could exacerbate the MV procedure (e.g. pulmonary embolism, neoplastic 
processes, etc.) can be excluded in only one scan. Another advantage for patients with severe 
MR is that CTA provides all this data in a single breath hold (27, 34). It might also be useful to 
study dynamic changes in the regional LV function (6). Also, according to recent studies, this 
procedure has minimal operator dependence (73). Furthermore, CTA provides direct 
visualisation and quantification of mitral calcifications. Another advantages of pre-procedural 
cardiac CTA are the possibility to find an ideal access point to guide echocardiography by 
identifying the intended intraprocedural epicardial access point and to predict LVOT obstruction 
by preprocedural device simulation (95). Although CTA is associated with many advantages, we 
cannot ignore the fact that – compared to echocardiography and CMR – it involves radiation 
exposure and iodinated contrast injection in MSCT. However, an adjustment of protocols can 
keep the radiation dose within the permissible limits, resulting in a dose reduction of up to 50-
70% and reducing the risk of contrast nephropathy (87).  The main challenge in cardiac CT is 
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temporal resolution. Despite high spatial resolution, compared to echocardiography and CMR, 
CTA has lower temporal resolution (about 72 ms for modern dual-source scanners). However, 
using a dual-source scanner gives twice as good temporal resolution because data reconstruction 
is possible with only 90 tube rotation and the temporal resolution ≤ 80 ms is enough to get good 
quality images for assessing cardiac structures (45)   
CT imaging is further influenced by artifacts caused by a rapid or irregular heart rhythm, which 
can affect the imaging quality of CT and represents another potential limitation/disadvantage. 
Despite these disadvantages, when used appropriately, patients would most likely benefit from 
CT, especially elderly patients who are potential candidates for percutaneous minimally invasive 
procedures. Before such procedures all images should be carefully assessed for any incidental 
cardiac and extracardiac findings that may delay treatment or affect overall patient’s prognosis 
and CTA can provide such assessment simultaneously. 
 
 
5.4 Study limitations 
The current study has some limitations. First, it was limited by its retrospective design. Second, 
only relatively few patients were included in each group. We included patients with FMR in the 
analysis, as these patients represent the group of patients that will potentially undergo TMVI in 
early clinical trials. Patients with degenerative MR or with extensive calcific changes of MA 
were not included in the analysis, representing another limitation. Despite the fact that all 
subjects in control group has no known cardiac abnormality or coronary artery disease, however,  
there is still remains a little uncertainty  of cardiac health, some kind of myocardial diseases 
(myocarditis, cardiomyopathy etc.) in them are unlikely, but not completely excluded.In our 
study we did not evaluate the intercomissural distance of the MA or the distance from the MA to 
the circumflex artery and coronary sinus and the aorto-trigonal distance, which could be 
considered another weak point of our work. This is an important area that requires further 
research. Another limitation is that our study concentrated on establishing the pre-procedural 
post-processing technique without a correlation to the clinical outcome. The limited temporal 
resolution of CT can represent another limitation of our study.  
However, to the extent of our knowledge, this is the first study that assesses and compares mitral 
valve dimensions and mobility, the subvalvular apparatus, LV hemodynamics, LA volume, 
aortomitral and LA-to-LV angles by MSCT in healthy subjects as controls and in patients with 





It is essential to optimise imaging acquisition protocols, in order to convey all relevant 
information for successful treatment planning. It should be noted that different devices may 
require specific measurements.   Our data highlight the importance of a careful analysis with the 
potential to optimize pre-procedural exposure and reduce the dose of radiation and contrast 
media.The significant differences in the mitral annular morphology between healthy patients and 
patients with FMR were presented, along with several changes between different sizing 
approaches of the mitral annulus throughout the entire cardiac cycle.  
A difference in the mobility of the mitral annulus was also identified; it is higher in healthy 
subjects than in patients with FMR. Considering the low mitral annulus mobility in patients with 
FMR and the relatively time-consuming assessment of mitral valve dimensions in all 10% 
phases of the RR interval using complex software, multiphase MSCT might not be necessary for 
planning transcatheter mitral valve interventions but may be replaced by dual-phase scans for 
example. This plays an important role in timing the pre-procedural analysis and determining the 
outcome of patients. Additionally, scans with lower number of phases would reduce radiation 
dose. However, using multiphase CTA should still be the favored mode in complicated cases.  
In summary, our study demonstrates that a non-invasive, comprehensive assessment of the 
anatomy, geometry and dynamics of the mitral valve and of its relationships with the 
surrounding structures by MSCT is feasible. For translation of these results into the daily clinical 
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